← 홈

Antibody · 흑색종

68개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 68개
AntibodystaleXencor, Inc.Phase 1

XmAb®808 (XmAb®808)

Head and Neck Squamous Cell Carcinoma; Melanoma Excluding Uveal Melanoma · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase1#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleBristol Myers SquibbPhase 1

ipilimumab (Yervoy®, Yervoy® (ipilimumab))

Melanoma (Excluding Uveal Melanoma); Cervical Carcinoma · HER2

#HER2#Antibody#Phase1#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleNational Cancer Institute (NCI)Phase 1

aflibercept (Eylea, VEGF Trap-Eye, Eylea HD, Ziv-Aflibercept)

Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Colorectal Carcinoma · FRα

#FR#Antibody#Phase1#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleBlokhin's Russian Cancer Resear…Phase 2

mFOLFOX6 + dabrafenib and cetuximab or panitumumab in the first line of therapy (mFOLFOX6 + dabrafenib and cetuximab or panitumumab in the first line of therapy)

Neoplasms · Neoplasms

#Neoplasms#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleBristol Myers SquibbPhase 3

nivolumab (Opdivo, nivolumab plus relatlimab)

Melanoma, Cutaneous Malignant · Melanoma, Cutaneous Malignant

#MelanomaCutaneousMalignant#Antibody#Phase3#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleBristol Myers SquibbPhase 2

nivolumab (Opdivo, relatlimab+nivolumab)

Melanoma · Melanoma

#Melanoma#Antibody#Phase2#항체#면역항체+2
효능 ORR 44.4%임상시험 1상태 ACTIVE
AntibodystaleBristol Myers SquibbPhase 2

nivolumab (Opdivo, relatlimab+nivolumab+rHuPH20)

Melanoma · Melanoma

#Melanoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleVanderbilt-Ingram Cancer CenterPreclinical

ticilimumab (ticilimumab)

Melanoma · Melanoma

#Melanoma#Antibody#Preclinical#항체#면역항체+2
임상시험 1상태 DISCONTINUED

4 / 4 페이지

← 이전다음 →